Updated on 16 July 2015
Vanderbilt University Medical Center (VUMC), the Human Vaccines Project, and the International AIDS Vaccine Initiative (IAVI) have announced that VUMC has become the Project's first scientific hub.
Incubated by IAVI, the Human Vaccines Project is a new public-private partnership that brings together leading academic research centers, industry, governments and nonprofits to accelerate the development of vaccines and immunotherapies against infectious diseases and cancers by decoding the human immune system.
"We are delighted that Vanderbilt University Medical Center will bring its world-class vaccine research and human immunology expertise to the Human Vaccines Project," said Mr Wayne C Koff, IAVI chief scientific officer and the Project's founder.
Under the collaboration, VUMC has pledged a multi-year commitment toward the Project which will include a large-scale global effort to decipher the "Human Immunome," the basic components of the human immune system, to enhance design of next-generation vaccines and immunotherapies.
"We are pleased to be the Project's flagship scientific partner. Vanderbilt's longstanding commitment to vaccine research and development will allow us to make valuable contributions toward accelerating the creation of new vaccines and therapies necessary to fight significant diseases," said Mr Jeff Balser, MD, PhD, Vanderbilt University's vice chancellor for Health Affairs and dean of the School of Medicine.